Anti-IL-23p19 antibody formulations
Grant
US12577297B2
Kind: B2
Mar 17, 2026
Assignee
Boehringer Ingelheim International GmbH
Inventors
Patrick Garidel, Torsten Schultz-Fademrecht
Abstract
The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2;b) a polyol; andc) a surfactant. The disclosed high concentration formulations are advantageously storage stable and suitable for subcutaneous administration.
CPC Classifications
C07K 16/244
C07K 2317/24
C07K 2317/515
C07K 2317/94
A61K 9/0019
A61K 9/08
A61K 39/3955
Filing Date
2020-09-08
Application No.
17014399
Claims
8